Evidence map›Paper›PMID 37870738›Full record

ArticleInvestigational new drugs2023

Antitumor activity of the new tyrphostin briva against BRAF

Khaled Saleh, Mai Al Sakhen, Sana Kanaan, Salem Yasin, Michael Höpfner, Lubna Tahtamouni, Bernhard Biersack

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Khaled SalehDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, 13115, Jordan.
Mai Al SakhenDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, 13115, Jordan.
Sana KanaanDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, 13115, Jordan.
Salem YasinDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, 13115, Jordan.
Michael HöpfnerInstitute of Physiology, Charité-Universitätsmedizin Berlin, Corporate Member of the Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Lubna TahtamouniDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, 13115, Jordan. lubnatahtamuni@hu.edu.jo.ORCID 0000-0001-8024-1944
Bernhard BiersackOrganic Chemistry Laboratory, University Bayreuth, Universitätsstrasse 30, 95440, Bayreuth, Germany. bernhard.biersack@yahoo.com.ORCID 0000-0001-7305-346X
Hashemite University · JOHumboldt-Universität zu Berlin · DEUniversity of Bayreuth · DE

Funding

Bayern Innovativ 2014-2668-SI-01/1The Hashemite University AM/16/13/10/2202791
6 · The paper itself

Abstract

Because of a reduced sensitivity of BRAF-mutant colorectal cancers to BRAF inhibitor treatment when compared with BRAF-mutant melanoma, it is essential to develop efficient drugs to cope with this disease. The new 2-(4-bromophenyl)-3-arylacrylonitrile compound Briva was prepared in one step from commercially available starting compounds. Briva and two known thiophene analogs (Thio-Iva and Thio-Dam) were tested for their cytotoxic activity against various tumor cell lines including colorectal and breast cancer cells. The antitumor activities of the test compounds were assessed in vitro via the MTT assay, DAPI staining of nuclei, RT-PCR and immunoblotting, wound healing, clonogenic assay, collagen I adhesion assay, and kinase inhibition assays. A selective activity of Briva was observed against BRAF

Indexed as

Antineoplastic AgentsColorectal NeoplasmsCell Line, TumorCell ProliferationHumansMutationProto-Oncogene Proteins B-rafTyrphostinsXenograft Model Antitumor AssaysAntineoplastic AgentsBRAF protein, humanProto-Oncogene Proteins B-rafTyrphostinsAnticancer DrugsBRAF-mutant tumorsBromophenyl derivativeColorectal cancerIsovanillinVEGFR2 inhibitors

Identifiers

PMID37870738
OpenAlexW4387866260

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.